Abstract: The present invention relates to compounds of the general formula I B—(CH—R1)n—C(?X2)-D ??(I) and pharmaceutically acceptable salts thereof including stereoisomers, to the use of the compounds for the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidosis, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus in mammals.

Abstract: The present invention discloses a method for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic ?-cells and to cause differentiation of pancreatic epithelial cells into insulin producing ?-cells. Oral administration a DP IV inhibitor causes the active form of GLP-1 to be preserved longer under physiological conditions. The extended presence of GLP-1, in particular in the pancreatic tissue facilitates differentiation and regeneration of the ?-cells already present that are in need of repair. These repaired insulin producing cells can contribute to the correction and maintenance of normal physiological glycemic levels.

Abstract: The present invention relates to specific inhibitors of the cysteine protease dipeptidyl peptidase I (DP I), which can be used in the treatment of malignant cell degeneration, immune deseases impaired wound healing and metabolic diseases of humans and are represented by the general formula in which R is a peptide or a branched or unbranched C1-C9 alkyl chain, a branched or unbranched C2-C9 alkenyl chain, a branched or unbranched C2-C9 alkynyl chain, a C3-C9 cycloalkyl, C4-C9 carbocyclic, C5-C14 aryl, C3-C9 heteroaryl, C3-C9 heterocyclic, all of the above residues optionally being substituted, the residue AS—AS is a dipeptide or a mimetic thereof, AS is an amino acid or a peptide mimetic thereof.

Abstract: The present invention relates dipeptidyl peptidase IV inhibition and, more particularly, relates to glutaminyl derivatives, wherein the glutamin residue is bound in a peptide manner to a moiety which imitates the amino acid residue prolin, especially to a nitrogen containing moiety, pharmaceutical compositions containing said compounds, and the use of said compounds in inhibiting dipeptidyl peptidase IV and dipeptidyl peptidase IV-like enzyme activity.

Abstract: The present invention relates to compounds that act as inhibitors of QC including those represented by the general formulae 1 to 9: 1

Abstract: The present invention discloses a method for the modulation of the enzymatic activity of prolyl endopeptidase in various human tissues and their biological effect on intracellular inositol (1,4,5) triphosphate concentration. The present invention also discloses the potentiation of endogenous neurological and intracellular signaling cascades by inhibition of prolyl endopeptidase activity. This invention further discloses the amplification of substance P mediated stimulation of IP3 concentration by inhibition of proline endopeptidase activity. The effect of reduced PEP activity on second messenger concentration indicates a novel intracellular function of this peptidase, which has an important impact on cognitive enhancements due to PEP inhibition.

Abstract: The present invention relates to prodrug compounds of inhibitors of dipeptidyl peptidase IV (DP IV), which prodrug compounds have the general formula A-B-C, wherein

Abstract: The present invention provides compounds of the formula: 1

Abstract: The invention relates to a steam iron with instantaneous vaporization comprising a water container (2), a steam chamber (32), an anti-drip device (80) and a drip device having a rod (4) which moves axially. According to the invention, the total stroke of the axially-moving rod (4) comprises a first stroke which provides the flow of water through the opening (520) of a module (5) that receives the water from the container (2) via the anti-drip device (80) and a second stroke which simultaneously opens a direct passage for the water to flow from the container (2) to the module (5) and moves the module (5) by opening a larger hole for the water to flow from the container to the steam chamber.

Abstract: The invention relates to a steam iron with instantaneous vaporisation comprising a water container (2), a steam chamber (32), an anti-drip device (80) and a drip device having a rod (4) which moves axially. According to the invention, the total stroke of the axially-moving rod (4) comprises a first stroke which provides the flow of water through the opening (520) of a module (5) that receives the water from the container (2) via the anti-drip device (80) and a second stroke which simultaneously opens a direct passage for the water to flow from the container (2) to the module (5) and moves the module (5) by opening a larger hole for the water to flow from the container to the steam chamber.

Abstract: The invention concerns a flash iron comprising a water reservoir (2), a flash chamber (32) and a drip device having an axially mobile rod (4) whereof the total stroke comprises a first travel enabling the steam to flow towards the orifice (520) of a module (5) and a second travel moving the module (5) by opening a wider orifice (220) for water passing from the reservoir (2) to the flash chamber (32). The invention is characterised in that the tightness between the reservoir (2), the module (5) and the flash chamber (32) is provided by a first compressed seal, and the tightness between the rod and the module is provided by a second compressed seal, the two seals being parts of one and the same elastomeric component (52) borne by the module (5).

Abstract: The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV and their use to modulate the substrate specificity of DP IV; methods of treatment of various DP IV mediated disorders; and screening methods for the identification of secondary binding sites on DP IV and DP IV-like enzymes.

Abstract: The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable attractin inhibitor causes the reduction of activity in the enzyme attraction or in isoforms thereof in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36), NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, t antihypertension and other neurological effects.

Abstract: The present invention relates to novel C-terminal truncated fragments and novel N-terminal modified analogues of gastric inhibitory polypeptide as well as various GIP analogues with a reduced peptide bond or alterations of the amino acids close to the dipeptidyl peptidase IV (DPIV)-specific cleavage site providing improved DPIV-resistance and prolonged half-life. Further the invention relates to novel analogs with different linkers between potential receptor binding sites of GIP.

Abstract: The invention concerns a flash iron comprising a water reservoir (2), a flash chamber (32) and a drip device having an axially mobile rod (4) whereof the total stroke comprises a first travel enabling the steam to flow towards the orifice (520) of a module (5) and a second travel moving the module (5) by opening a wider orifice (220) for water passing from the reservoir (2) to the flash chamber (32). The invention is characterised in that the tightness between the reservoir (2), the module (5) and the flash chamber (32) is provided by a first compressed seal, and the tightness between the rod and the module is provided by a second compressed seal, the two seals being parts of one and the same elastomeric component (52) borne by the module (5).

Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.

Abstract: The present invention provides compounds of the formula: 1

Abstract: The present invention relates to compounds of the general formula 1 1

Abstract: Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in mammals.

Abstract: This invention involves a compound represented by the general formula (I): 1